Skip to content

To check Effect of Bilwadi Kwath in Medoroga.

A RANDOMISED CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFICACY OF BILWADI KWATH IN THE MANAGEMENT OF MEDOROGA WITH SPECIAL REFERENCE TO DYSLIPIDEMIA. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106985
Enrollment
60
Registered
2026-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Sponsors

Dr Darshan Lotan Patil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed and confirmed cases of Dyslipidaemia based on investigation.Patient with DM range 150 mg/dl To 250 mg/dl.Patient between the age group of 30-60 years of either sex who will fulfil the criteria of diagnosis.Patients willing and able to participate for 60 days duration.Patients who are ready to give consent with firm home address and contact no. which is readily accessible during coarse of trial.Advice to take Takra, Madhu, Ushodaka Laghu supachya Ahara.

Exclusion criteria

Exclusion criteria: Patient not willing for the trial.Patient with Hypertension BP less than 160/100 mm of Hg.Patient having illness like Diabetes mellitus above 250 mg/dl, Tuberculosis, Carcinoma, or major illness like renal or Liver disorders.Patient having past-history of Myocardial Infarction,Unstable angina,and congestive cardiac failure.Patient below 30 years and above 60 years of age.History of hypersensitivity to any trial drug or their ingredients.Pregnant females and lactating mothers.Advice to avoid Godhuma, Navannapana,Shali,Dadhi,Ghrita,Navneet,Diwaswapna.

Design outcomes

Primary

MeasureTime frame
Reduction in the Haematological parameters of Dyslipidaemia-Lipid Profile (Total Serum Cholesterol, Serum Triglycerides, Serum LDL Cholesterol, Cholesterol, Serum VLDL Cholesterol).Timepoint: 60 days

Secondary

MeasureTime frame
Subjective improvement in symptoms is the secondary outcome.Timepoint: 60 days

Countries

India

Contacts

Public ContactDarshan Patil

Late Kedari Redekar Ayurved Mahavidyalaya Gadhinglaj Kolhapur 416502

drjayantpatil07@gmail.com8600660485

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026